Betta Reconciled Depreciation from 2010 to 2024

300558 Stock   52.69  1.11  2.06%   
Betta Pharmaceuticals' Reconciled Depreciation is increasing over the years with slightly volatile fluctuation. Reconciled Depreciation is expected to dwindle to about 188.1 M. From 2010 to 2024 Betta Pharmaceuticals Reconciled Depreciation quarterly data regression line had arithmetic mean of  124,113,031 and r-squared of  0.71. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2010-12-31
Previous Quarter
303.5 M
Current Value
188.1 M
Quarterly Volatility
76.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Betta Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Betta Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 32.1 M, Selling General Administrative of 632.6 M or Total Revenue of 1.4 B, as well as many indicators such as . Betta financial statements analysis is a perfect complement when working with Betta Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Betta Pharmaceuticals Technical models . Check out the analysis of Betta Pharmaceuticals Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Betta Stock

Betta Pharmaceuticals financial ratios help investors to determine whether Betta Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Betta with respect to the benefits of owning Betta Pharmaceuticals security.